Patient-reported outcomes (PROs) measure aspects of a patient's health status that comes directly from the patient, including health-related quality of life (HRQoL). HRQoL instruments provide a means of assessing treatment benefit and can be important tools in clinical research and practice.59-61 HRQoL is becoming an increasingly important assessment tool in multiple myeloma, given the improved survival outcomes from recent treatment advances. There are multiple well-validated instruments available which can be used in clinical trials to facilitate comparisons between treatments.60,62

Select HRQoL Instruments

Instrument60,62,63,64 Use Domains/Categories Measurement
EORTC-QLQ-C30 Cancer Patients Global health status/QoL Functional domains: physical, role, emotional, cognitive and social
Symptom domains: fatigue, nausea, pain
4-point Likert scale (not at all, a little, quite a bit, very much)65
EORTC-QLQ-MY20*(MY24) MM-specific tool used with QLQ-C30 Disease symptoms, side effects of treatment, body image and future perspectives 4-point Likert scale (not at all, a little, quite a bit, very much)65,66
EORTC-QLQ-CIPN20 Chemotherapy-induced peripheral neuropathy Sensory, motor and autonomic subscales 4-point Likert scale (not at all, a little, quite a bit, very much)67
FACT-MM MM-specific tool Physical, social, emotional and functional well-being and additional concerns 5-point Likert scale (not at all, a little bit, somewhat, quite a bit, very much)68
EuroQoL-5D General HRQoL questionnaire Mobility, self care, usual activities, pain/discomfort, anxiety/depression 3L: Levels 1-3 (no problem, some problems, extreme problems) 5L: Levels 1-5 (no problem, slight problems, moderate problems, severe problems, extreme problems)69
*Validated for MM and widely used.

CIPN, chemotherapy-induced peripheral neuropathy; EORTC, European Organisation for Research and Treatment of Cancer; FACT, Functional Assessment of Cancer Therapy; QLQ, quality of life questionnaire